<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zhu X</submitter><funding>Expert Workstation for Jingcheng Dong in Yunnan Province</funding><pagination>6842530</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9626231</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>2022</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Cycloastragenol (CAG) has been reported to alleviate airway inflammation in ovalbumin- (OVA-) induced asthmatic mice. However, its specific mechanisms remain unclear.&lt;h4>Objective&lt;/h4>This study is aimed at investigating the effects of CAG on asthma, comparing its efficacy with dexamethasone (DEX), and elucidating the mechanism of CAG's regulation.&lt;h4>Methods&lt;/h4>The asthma mouse model was induced by OVA. CAG at the optimal dose of 125 mg/kg was given every day from day 0 for 20-day prevention or from day 14 for a 7-day treatment. We observed the preventive and therapeutic effects of CAG in asthmatic mice by evaluating the airway inflammation, AHR, and mucus secretion. Lung proteins were used for TMT-based quantitative proteomic analysis to enunciate its regulatory mecha</pubmed_abstract><journal>Oxidative medicine and cellular longevity</journal><pubmed_title>TMT-Based Quantitative Proteomic Analysis Reveals Downregulation of ITGAL and Syk by the Effects of Cycloastragenol in OVA-Induced Asthmatic Mice.</pubmed_title><pmcid>PMC9626231</pmcid><funding_grant_id>82174170</funding_grant_id><funding_grant_id>21S21902500</funding_grant_id><funding_grant_id>20210101</funding_grant_id><pubmed_authors>Ruan Z</pubmed_authors><pubmed_authors>Li C</pubmed_authors><pubmed_authors>Chen M</pubmed_authors><pubmed_authors>Zhu H</pubmed_authors><pubmed_authors>Zhou Y</pubmed_authors><pubmed_authors>Wei Y</pubmed_authors><pubmed_authors>Yu H</pubmed_authors><pubmed_authors>Huang X</pubmed_authors><pubmed_authors>Dong J</pubmed_authors><pubmed_authors>Zhu X</pubmed_authors><pubmed_authors>Liu B</pubmed_authors><pubmed_authors>Xu W</pubmed_authors><pubmed_authors>Shi H</pubmed_authors><pubmed_authors>Sun J</pubmed_authors></additional><is_claimable>false</is_claimable><name>TMT-Based Quantitative Proteomic Analysis Reveals Downregulation of ITGAL and Syk by the Effects of Cycloastragenol in OVA-Induced Asthmatic Mice.</name><description>&lt;h4>Background&lt;/h4>Cycloastragenol (CAG) has been reported to alleviate airway inflammation in ovalbumin- (OVA-) induced asthmatic mice. However, its specific mechanisms remain unclear.&lt;h4>Objective&lt;/h4>This study is aimed at investigating the effects of CAG on asthma, comparing its efficacy with dexamethasone (DEX), and elucidating the mechanism of CAG's regulation.&lt;h4>Methods&lt;/h4>The asthma mouse model was induced by OVA. CAG at the optimal dose of 125 mg/kg was given every day from day 0 for 20-day prevention or from day 14 for a 7-day treatment. We observed the preventive and therapeutic effects of CAG in asthmatic mice by evaluating the airway inflammation, AHR, and mucus secretion. Lung proteins were used for TMT-based quantitative proteomic analysis to enunciate its regulatory mecha</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2026-05-28T21:27:01.179Z</modification><creation>2025-04-05T14:54:29.781Z</creation></dates><accession>S-EPMC9626231</accession><cross_references><pubmed>36329800</pubmed><doi>10.1155/2022/6842530</doi></cross_references></HashMap>